FilingReader Intelligence
Yiling Pharmaceutical secures 150m yuan funding, Macau registration
July 11, 2025 at 08:52 AM UTC•By FilingReader AI
Shijiazhuang Yiling Pharmaceutical approved using up to 150 million yuan of idle raised funds to supplement working capital for 12 months, aiming to improve capital efficiency and reduce financial costs.
The company's Macau subsidiary obtained registration for an allergic rhinitis treatment, with plans to commence production and sales promptly.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
Announcement on the Acquisition of the Macao Chinese Patent Medicine Registration Certificate for Qifangbitong TabletsJuly 11, 2025 at 08:00 AM UTC
China International Capital Corporation Limited's review opinion on Yiling Pharmaceutical's use of part of the idle non-public offering funds to temporarily supplement working capitalJuly 11, 2025 at 08:00 AM UTC
Announcement on Using Part of the Idle Non-public Offering Funds to Temporarily Supplement Working CapitalJuly 11, 2025 at 08:00 AM UTC
SZSE:002603•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Shijiazhuang Yiling Pharmaceutical publishes news
Free account required • Unsubscribe anytime